VC: Affymax leads venture rounds with $60M



Affymax pockets $60M in fourth round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Affymax
Palo Alto, CA

$60 million
fourth round

JAFCO, Bear Stearns Health Innoventures

Much of the money will go to a Phase II clinical program for Hematide in patients with chronic kidney disease and cancer.

Ilypsa
Santa Clara, CA

$36 million
round two

US Venture Partners, Johnson & Johnson Development Corporation, and Delphi Ventures

Ilypsa will use the funds to complete preclinical and initiate clinical development of their two lead compounds ILY-101, a metal-free, polymeric phosphate binder, and ILY-105, a novel potassium-binding polymer.

Labcyte
Sunnyvale, CA

$21 million
third round

Cross Atlantic Partners

Labcyte is developing its low-volume liquid handling business, which is based on a proprietary technology for using focused acoustics to precisely transfer nanoliters of liquid.

Peptimmune
Cambridge, MA

$20.4 million
third round

New Enterprise Associates

Peptimmune's lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity.

BrainCells
San Diego

$17.7 million
round one

Technology Partners, Oxford Bioscience Partners, and Bay City Capital

The money will go to identify one or more late-stage clinical compounds currently under development for a CNS indication.

APT Pharmaceuticals
Tucson, AZ

$6 million
round one

Charter Life Sciences

The funds go to support a Phase II trial of an inhaled version of hydroxychloroquine for asthma.

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.